Kura Oncology details 'aggressive' approach in first-line AML

Nicole DeFeudis

Editor

SAN DIEGO — As Kura Oncology awaits key pivotal data in relapsed or refractory acute myeloid leukemia, the company is going all in on combinations in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Kura Oncology details 'aggressive' approach in first-line AML

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Senators ask FDA to dig into 'misleading' Super Bowl ad from Hims

Pliant pauses Phase 2b lung fibrosis study after safety board recommendation, shares plummet

Updated: Bay Area biotech VC to shut down 15 months after launch, sources say, after key investor pulls out

Major FDA staff cuts would slow drug reviews, experts say

AbbVie wins FDA approval for new antibiotic to treat complex intra-abdominal infections

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Ku­ra On­col­o­gy de­tails 'ag­gres­sive' ap­proach in first-line AML

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Kura Oncology details 'aggressive' approach in first-line AML